D

Dispatch Biotherapeutics

Cloud-based software linking labs and providers

Vice President - Biometrics

Full-TimePosted on 10/20/2026
$280k - $355k+ Equity
Expert
PhD
San Francisco, CA, USA
In Person
Biology & BiotechQuantitative Biology & Biostatistics

About the job

Requirements
  • A Ph.D. in Statistics, Biostatistics, or a related quantitative field is required.
  • At least 15 years of clinical development statistics experience in the biopharmaceutical industry, with progressive leadership responsibility, including leading a biostatistics or biometrics function or serving as lead statistician across multiple programs.
  • Substantial hands-on oncology experience, including designing and analyzing early-phase oncology studies and familiarity with oncology endpoints and response criteria such as RECIST and time-to-event endpoints.
  • Demonstrated expertise in innovative early-phase designs, including dose-escalation and dose-expansion approaches.
  • Direct experience leading statistical contributions to FDA interactions and regulatory submissions, such as INDs and end-of-phase meetings, and contributing to at least one BLA, NDA, or MAA.
  • Strong working knowledge of ICH guidelines, including E9/E9(R1), GCP, CDISC standards, and relevant FDA guidance.
  • A track record of selecting and overseeing CROs and functional service providers in an outsourced operating model.
  • Hands-on proficiency in SAS and/or R, and willingness to personally perform and quality-check analyses.
  • Comfort operating as a leader with a small team, initially without a team, and a strong desire to build.
  • Ability to work collaboratively across functions and influence peers and leaders without relying on hierarchy.
  • Strong organizational, problem-solving, and time-management skills, with judgment to manage competing priorities.
  • Ability to operate in a fast-paced, entrepreneurial environment where processes are still being built.
  • Strong verbal and written communication skills, including translating complex technical concepts for clinical, scientific, executive, and external audiences.
  • Comfort giving and inviting candid feedback and flagging risks early.
Responsibilities
  • Build the biometrics function, including its strategy, operating model, standard operating procedures, data standards such as CDISC SDTM/ADaM, templates, and analysis infrastructure, right-sized for the company’s stage and designed to scale.
  • Serve as hands-on lead statistician for the ongoing first-in-human study by authoring and reviewing statistical sections of protocols, statistical analysis plans, TLF specifications, and data review plans, and performing or quality-checking key analyses.
  • Provide statistical leadership on early-phase study design, including dose-escalation and dose-expansion strategies, model-based and Bayesian dose-finding methods, two-stage and single-arm designs with efficacy/futility boundaries, and dose optimization consistent with FDA and global health authority expectations.
  • Interpret emerging safety and efficacy data, including ORR, duration of response, PFS, and OS, to inform safety review committees, interim analyses, and program go/no-go decisions.
  • Partner with Clinical Development and Program and Portfolio Management on clinical development plans and target product profiles, contributing sample-size, probability-of-success, and scenario analyses to evaluate potential paths to registration.
  • Partner with the VP of Regulatory Affairs to lead statistical content for regulatory interactions and submissions, including briefing documents, IND amendments, annual reports/DSURs, end-of-phase meetings, and expedited program requests, and plan for integrated analyses and BLA readiness.
  • Oversee clinical data management with Clinical Operations, including EDC build, data quality and cleaning strategies, data review, and database lock, ensuring data integrity and inspection readiness.
  • Select, contract, and manage CROs and biometrics vendors, holding them accountable for quality, timelines, and budget.
  • Collaborate with Translational Science to integrate biomarker, pharmacokinetic/cellular kinetic, and exploratory data into analyses that deepen understanding of mechanism and patient response.
  • Evaluate and apply innovative methods where useful, including artificial intelligence and machine learning applications, external controls, and real-world data approaches to contextualize single-arm results.
  • Ensure accurate and appropriate statistical framing of external data communications, including congress abstracts, presentations, publications, and data shared with potential partners and investors.
  • Scale the function as the company evolves toward a multi-program, multi-region clinical portfolio by hiring thoughtfully and developing team members as business needs grow.
Desired Qualifications
  • Experience with cell therapy, such as CAR T, or gene therapy programs, including analysis of cellular kinetics and immune-related safety events such as CRS and ICANS.
  • Experience in oncology, especially solid tumors and gastrointestinal cancers.
  • Experience supporting expedited regulatory pathways, including Breakthrough Therapy designation and accelerated approval based on single-arm studies.
  • Experience with Bayesian methods, external control arms, or real-world evidence in a regulatory context.
  • Prior experience as the first or founding biometrics leader at an early-stage biotech.
  • Experience supporting ex-US clinical studies.
  • Experience supporting business development diligence, financing, or IPO-related data activities.

About the company

D

Dispatch Biotherapeutics

View

Dispatch Bio provides a cloud-based software platform for infectious disease diagnostics. It connects patients, providers, and laboratories to deliver faster, more accurate test results. The core product is a SaaS system that laboratories use to manage test orders, workflows, and results reporting, while healthcare providers use it to order tests and receive timely results for patients. The platform integrates the entire diagnostic process in a single system, reducing turnaround times and streamlining communication across the care team. Compared with typical lab software, Dispatch Bio focuses on end-to-end workflow integration, strong data security and regulatory compliance, and a B2B model that targets diagnostic labs and healthcare providers. Its goal is to modernize diagnostic testing to enable quicker diagnoses and better patient management in infectious diseases.

Company Size

51-200

Company Stage

Series A

Total Funding

$216M

Headquarters

Philadelphia, Pennsylvania

Founded

2022

Get referred to Dispatch Biotherapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 6, 2026 first-patient dosing de-risks execution and strengthens investor credibility.
  • Fast Track designation accelerates FDA engagement and potential 2027 efficacy readouts.
  • August 2026 CARsgen collaboration expands Flare into China with zevor-cel.

What critics are saying

  • DISP-10 depends on viral delivery, CAR-T trafficking, and antigen stability; one failure kills efficacy.
  • Single-platform concentration leaves Dispatch exposed if 2026 safety signals derail Flare.
  • No commercial revenue makes a failed Phase 1 an existential capital trap before 2028.

What makes Dispatch Biotherapeutics unique

  • Dispatch pairs tumor-specific virus DV-10 with CAR-T, creating a programmable antigen platform.
  • Carl June, ARCH, PICI, and BMS anchor Dispatch's 2025-2026 solid-tumor strategy.
  • August 2026 first-patient dosing validates Dispatch's clinic-ready manufacturing and trial engine.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Vision Insurance
  • Dental Insurance
  • Life Insurance
  • Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Business Wire
Apr 27th, 2026
Dispatch Bio's SEND T cell armoring strategy shows 200X+ therapeutic window in solid tumors

Dispatch Bio presented preclinical data on its SEND T cell armoring strategy at the American Society of Gene & Cell Therapy 2026 Annual Meeting in Boston. The technology uses a synthetic cytokine receptor to simultaneously activate multiple pathways for optimal T cell function, designed to overcome limitations in the tumour microenvironment. Preclinical results showed SEND-armoured CAR T cells achieved tumour clearance at low doses with a therapeutic window exceeding 200-fold. The treatment demonstrated efficacy with or without lymphodepleting chemotherapy. Single-cell RNA sequencing revealed simultaneous enrichment of effector and memory gene programmes within individual cells, indicating robust expansion without exhaustion. Dispatch Bio believes SEND could apply broadly across engineered T cell approaches, including autologous CAR T therapies and TCR-based treatments. The company's Flare platform combines immunotherapy with tumour-specific virus engineering for solid tumour treatment.

BioSpace
Nov 5th, 2025
Dispatch Bio Unveils First Clinical Program and Presents Data Supporting Flare Platform at Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting

Dispatch Bio unveils first clinical program and presents data supporting Flare platform at Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. November 5, 2025 | Encouraging preclinical data validate Dispatch's scientific approach and support advancement of DISP-10 toward clinical development in 2026 PHILADELPHIA & SAN FRANCISCO-(BUSINESS WIRE)-Dispatch Bio, a biotechnology company developing a universal treatment for solid tumors, today announced preclinical data supporting its first therapeutic program planned to enter the clinic, DISP-10, and its first-in-class Flare platform, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. Immunotherapies have had limited success in solid tumors due to the lack of tumor-specific targets and a profoundly immunosuppressive microenvironment. Dispatch's Flare platform addresses these barriers by systemically delivering a tumor-specific virus that paints a universal synthetic antigen (Flare) on tumor cells, enabling precise recognition by T cells, while reshaping the tumor microenvironment to support immune activity. Data presented at SITC (Abstract 394) demonstrate strong and consistent tumor labeling, iterative viral amplification and tumor cell clearance across multiple epithelial tumor models. "These data show that delivering engineered targets specifically to tumor cells allows us to control antigen specificity, while also reprogramming the tumor microenvironment," said Lex Johnson, Ph.D., Co-Founder and Chief Platform Officer. "We are excited to start with CAR T as our first program, and because the Flare approach is modular and not restricted to CAR T cells, it can be extended across multiple immunotherapy modalities." The company also presented preclinical findings from DISP-10, its first therapeutic candidate (Abstract 393). DISP-10 pairs DV-10, a tumor-targeted virus expressing a modified BCMA antigen (dBCMA) and the immune-stimulatory cytokine IL-18 and chemokine CXCL9, with a clinically validated BCMA-directed CAR T. The viral component installs the target and drives local immune activation, enabling robust CAR T function in solid tumors. DISP-10 demonstrated potent anti-tumor responses in numerous in vitro and in vivo models, with no activity observed in healthy cells. Dispatch plans to initiate a first-in-human Phase 1 study in 2026 to evaluate DISP-10 across multiple solid tumor types. "DISP-10 creates the right biological context for CAR T cells to function in solid tumors," said Barbra Sasu, Ph.D., Chief Scientific Officer. "The consistency of activity seen with various BCMA-targeted therapies across tumor models gives us confidence in its clinical potential." Dispatch also announced a clinical supply and collaboration agreement with Bristol Myers Squibb (BMS). Under the agreement, BMS will supply idecabtagene vicleucel (ide-cel) as the CAR T-cell component for Dispatch's first U.S. Phase 1 trial of DISP-10. DV-10, emerging from the Flare platform, provides the tumor-specific targeting and immune activation necessary for CAR T-cell function in solid tumors. Please see full Prescribing Information for idecabtagene vicleucel (ide-cel), including Boxed WARNINGS and Medication Guide. About Dispatch Bio Established in 2022, Dispatch Bio was founded with a bold purpose: to help create a world where all cancer patients can be cured. To achieve this, the company is engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform. This novel approach combines the strengths of immunotherapy with a tumor-specific virus, both engineered to clear tumor cells with precision and power. Dispatch has operations in Philadelphia and San Francisco, with access to world-class researchers. To learn more, visit www.dispatchbio.com and follow us on LinkedIn and X.

Fierce Biotech
Jul 23rd, 2025
Cancer biotech Dispatch unveils with $216M and CAR-T pioneer Carl June as cofounder

Dispatch Bio has unveiled with $216 million and the lofty goal of creating a universal treatment for solid tumors using a new immunotherapy approach. | Dispatch Bio has unveiled with $216 million and the lofty goal of creating a universal treatment for solid tumors using a new immunotherapy approach.